СибНСХБ

Вид поиска

Область поиска

Найдено в других БД

Формат представления найденных документов:
библиографическое описание	краткий	полный

Отсортировать найденные документы по:
автору	заглавию	году издания	типу документа

Поисковый запрос: (<.>S=КОНТРОЛЬ ЗА ГЛЮКОЗОЙ КРОВИ<.>)

Общее количество найденных документов : 2
Показаны документы с 1 по 2

Вид документа : Статья из журнала

РЖ ВИНИТИ 76 (BI31) 95.08-04Т3.188

Автор(ы) : Wolever T.M.S., Radmard R., Chiasson J.-L., Hunt J.A., Josse R.G., Palmason C., Rodger N.W., Ross S.A., Ryan E.A., Tan M.H.
Заглавие : One-year acarbose treatment raises fasting serum acetate in diabetic patients
Источник статьи : Diabet. Med. - 1995. - Vol. 12, N 2. - С. 164-172
Аннотация: 'альфа'-Glucosidase inhibitors such as acarbose improve blood glucose control in diabetes by delaying or reducing carbohydrate absorption. The fermentation of malabsorbed carbohydrate in the colon is associated with the production of gas, leading to flatulence, and short chain fatty acids such as acetate, which may have systemic effects. To see if acarbose raised fasting serum acetate in diabetic patients, we studied 85 subjects selected from the 267 who had completed a 1-year, double-blind, placebo-controlled, parallel design study of the effects of acarbose in the treatment of diabetes. At baseline, there was no significant difference between the 44 subjects subsequently randomized to placebo and the 41 randomized to acarbose, respectively, in fasting serum acetate (80'+-'5 vs 71'+-'4 'мю'moll{-1}) or glycosylated haemoglobin (HbA[1C]; 7.2'+-'0.3 vs 7.4'+-'0.3%). Compared to placebo, acarbose treatment significantly increased fasting serum acetate by 11'+-'4 vs 2'+-'3 'мю'moll{-1} (p 0.02) and reduced HbA[1C] by -0.59'+-'0.16 vs -0.13'+-'0.20% (p 0.02). Acarbose treatment had no significant effect on serum cholesterol or non-esterified fatty acids, but was associated with a significant increase in flatulence. There was no relationship between changes in serum acetate and changes in HbA[1C], serum cholesterol or symptoms. We conclude, in subjects with diabetes who tolerate therapy for a 1-year period, that acarbose treatment increases serum acetate. The magnitude of change in acetate was unrelated to side-effects or changes in blood glucose control or serum lipids
ГРНТИ : 76.31.29
Предметные рубрики: САХАРНЫЙ ДИАБЕТ
АКАРБОЗА
ДЛИТЕЛЬНОЕ ПРИМЕНЕНИЕ
КОНТРОЛЬ ЗА ГЛЮКОЗОЙ КРОВИ
ЛИПИДЫ СЫВОРОТКИ
БОЛЬНЫЕ
Дата ввода:

Вид документа : Статья из журнала

РЖ ВИНИТИ 34 (BI27) 96.01-04М6.295

Автор(ы) : Wolever T.M.S., Radmard R., Chiasson J.-L., Hunt J.A., Josse R.G., Palmason C., Rodger N.W., Ross S.A., Ryan E.A., Tan M.H.
Заглавие : One-year acarbose treatment raises fasting serum acetate in diabetic patients
Источник статьи : Diabet. Med. - 1995. - Vol. 12, N 2. - С. 164-172
Аннотация: 'альфа'-Glucosidase inhibitors such as acarbose improve blood glucose control in diabetes by delaying or reducing carbohydrate absorption. The fermentation of malabsorbed carbohydrate in the colon is associated with the production of gas, leading to flatulence, and short chain fatty acids such as acetate, which may have systemic effects. To see if acarbose raised fasting serum acetate in diabetic patients, we studied 85 subjects selected from the 267 who had completed a 1-year, double-blind, placebo-controlled, parallel design study of the effects of acarbose in the treatment of diabetes. At baseline, there was no significant difference between the 44 subjects subsequently randomized to placebo and the 41 randomized to acarbose, respectively, in fasting serum acetate (80'+-'5 vs 71'+-'4 'мю'moll{-1}) or glycosylated haemoglobin (HbA[1C]; 7.2'+-'0.3 vs 7.4'+-'0.3%). Compared to placebo, acarbose treatment significantly increased fasting serum acetate by 11'+-'4 vs 2'+-'3 'мю'moll{-1} (p 0.02) and reduced HbA[1C] by -0.59'+-'0.16 vs -0.13'+-'0.20% (p 0.02). Acarbose treatment had no significant effect on serum cholesterol or non-esterified fatty acids, but was associated with a significant increase in flatulence. There was no relationship between changes in serum acetate and changes in HbA[1C], serum cholesterol or symptoms. We conclude, in subjects with diabetes who tolerate therapy for a 1-year period, that acarbose treatment increases serum acetate. The magnitude of change in acetate was unrelated to side-effects or changes in blood glucose control or serum lipids
ГРНТИ : 34.39.39
Предметные рубрики: САХАРНЫЙ ДИАБЕТ
АКАРБОЗА
ДЛИТЕЛЬНОЕ ПРИМЕНЕНИЕ
КОНТРОЛЬ ЗА ГЛЮКОЗОЙ КРОВИ
ЛИПИДЫ СЫВОРОТКИ
БОЛЬНЫЕ
Дата ввода:

"Электронные каталоги и базы данных библиотек СО РАН"

© Международная Ассоциация пользователей и разработчиков электронных библиотек и новых информационных технологий
(Ассоциация ЭБНИТ)

rtvarBDview(" результаты поиска","20190607010228","4682442");

Вид поиска